Ole Hvilsted Olsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9895641/publications.pdf Version: 2024-02-01



OLE HVILSTED OLSEN

#	Article	IF	CITATIONS
1	Inhibitory Properties of Separate Recombinant Kunitz-Type-Protease-Inhibitor Domains from Tissue-Factor-Pathway Inhibitor. FEBS Journal, 1996, 235, 310-316.	0.2	77
2	Allosteric Activation of Coagulation Factor VIIa Visualized by Hydrogen Exchange. Journal of Biological Chemistry, 2006, 281, 23018-23024.	3.4	52
3	A combined structural dynamics approach identifies a putative switch in factor VIIa employed by tissue factor to initiate blood coagulation. Protein Science, 2007, 16, 671-682.	7.6	30
4	The Origins of Enhanced Activity in Factor VIIa Analogs and the Interplay between Key Allosteric Sites Revealed by Hydrogen Exchange Mass Spectrometry. Journal of Biological Chemistry, 2008, 283, 13378-13387.	3.4	28
5	Allosteric activation of coagulation factor VIIa. Frontiers in Bioscience - Landmark, 2011, 16, 3156.	3.0	24
6	ADAMDEC1 Is a Metzincin Metalloprotease with Dampened Proteolytic Activity. Journal of Biological Chemistry, 2013, 288, 21367-21375.	3.4	24
7	Sites Involved in Intra- and Interdomain Allostery Associated with the Activation of Factor VIIa Pinpointed by Hydrogen-Deuterium Exchange and Electron Transfer Dissociation Mass Spectrometry. Journal of Biological Chemistry, 2014, 289, 35388-35396.	3.4	20
8	Molecular Basis of Enhanced Activity in Factor VIIa-Trypsin Variants Conveys Insights into Tissue Factor-mediated Allosteric Regulation of Factor VIIa Activity. Journal of Biological Chemistry, 2016, 291, 4671-4683.	3.4	16
9	Activation loop 3 and the 170 loop interact in the active conformation of coagulation factor VIIa. FEBS Journal, 2009, 276, 3099-3109.	4.7	11
10	Prevention of β Strand Movement into a Zymogen-like Position Does Not Confer Higher Activity to Coagulation Factor VIIa. Biochemistry, 2004, 43, 14096-14103.	2.5	10
11	Evidence for Restricted Reactivity of ADAMDEC1 with Protein Substrates and Endogenous Inhibitors. Journal of Biological Chemistry, 2015, 290, 6620-6629.	3.4	10
12	Releasing the brakes in coagulation Factor IXa by co-operative maturation of the substrate-binding site. Biochemical Journal, 2016, 473, 2395-2411.	3.7	9
13	Allostery in Coagulation Factor VIIa Revealed by Ensemble Refinement of Crystallographic Structures. Biophysical Journal, 2019, 116, 1823-1835.	0.5	7
14	Beating tissue factor at its own game: Design and properties of a soluble tissue factor–independent coagulation factor VIIa. Journal of Biological Chemistry, 2020, 295, 517-528.	3.4	7
15	Conformational Plasticity-Rigidity Axis of the Coagulation Factor VII Zymogen Elucidated by Atomistic Simulations of the N-Terminally Truncated Factor VIIa Protease Domain. Biomolecules, 2021, 11, 549.	4.0	7
16	Recombinant coagulation factor VIIa labelled with the <i>fac</i> â€ ^{99 m} Tc(CO) ₃ â€core: synthesis and <i>in vitro</i> evaluation of a putative new radiopharmaceutical for imaging in acute bleeding lesion. Journal of Labelled Compounds and Radiopharmaceuticals. 2011, 54, 214-219.	1.0	6
17	The length of the linker between the epidermal growth factorâ€like domains in factor VIIa is critical for a productive interaction with tissue factor. Protein Science, 2014, 23, 1717-1727.	7.6	6
18	Engineering of a membrane-triggered activity switch in coagulation factor VIIa. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12454-12459.	7.1	6

#	Article	IF	CITATIONS
19	A systematic approach for evaluating the role of surface-exposed loops in trypsin-like serine proteases applied to the 170 loop in coagulation factor VIIa. Scientific Reports, 2022, 12, 3747.	3.3	2